Stock listing
NASDAQ:PASG Passage Bio, Inc. Stock
Home listing (NASDAQ) of Passage Bio, Inc.
Follow Passage Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PASG
$3.92 USD -0.21 (-5.2%)
Close on Nov 20, 2026
- Day range
- $3.51 – $3.94 USDNov 20, 2026
- Volume
- 27,965 sharesNov 20, 2026
- Market cap
- $12.61M USDAt the close on Nov 20, 2026 · price × 3.22M shares outstanding
- 52-week range
- $3.29 – $20.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $92,068 USDMedian day 15,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PASG · Home | $3.92 USD | -0.215 (-5.2%) | 27,965 | $3.65 | $3.94 | $3.51 | $4.135 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PASG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.92 | -0.215 | -5.2% | $3.65 | $3.94 | $3.51 | 27,965 | |
| $4.135 | -0.085 | -2.0% | $4.13 | $4.24 | $3.769 | 14,487 | |
| $4.22 | +0.09 | +2.2% | $4.04 | $4.25 | $3.91 | 24,651 | |
| $4.13 | -0.12 | -2.8% | $4.12 | $4.20 | $3.84 | 16,997 | |
| $4.25 | +0.24 | +6.0% | $4.055 | $4.25 | $4.03 | 11,873 | |
| $4.01 | +0.01 | +0.2% | $4.00 | $4.09 | $3.49 | 12,365 | |
| $4.00 | +0.22 | +5.8% | $3.86 | $4.00 | $3.80 | 27,915 | |
| $3.78 | +0.35 | +10.2% | $3.47 | $3.78 | $3.43 | 29,608 | |
| $3.43 | -0.545 | -13.7% | $3.66 | $3.75 | $3.43 | 4,847 | |
| $3.975 | +0.515 | +14.9% | $3.39 | $4.00 | $3.39 | 21,866 | |
| $3.46 | -0.05 | -1.4% | $3.52 | $3.56 | $3.39 | 28,146 | |
| $3.51 | +0.11 | +3.2% | $3.459 | $3.69 | $3.45 | 25,281 | |
| $3.40 | +0.08 | +2.4% | $3.40 | $3.48 | $3.33 | 7,687 | |
| $3.32 | -0.13 | -3.8% | $3.45 | $3.55 | $3.32 | 11,137 | |
| $3.45 | -0.07 | -2.0% | $3.605 | $3.605 | $3.45 | 7,173 | |
| $3.52 | +0.19 | +5.7% | $3.44 | $3.83 | $3.44 | 16,686 | |
| $3.33 | -0.02 | -0.6% | $3.40 | $3.565 | $3.30 | 8,034 | |
| $3.35 | -0.009 | -0.3% | $3.31 | $3.40 | $3.31 | 3,992 | |
| $3.359 | -0.011 | -0.3% | $3.365 | $3.365 | $3.359 | 1,602 | |
| $3.37 | -0.14 | -4.0% | $3.63 | $3.63 | $3.345 | 21,500 | |
| $3.51 | -0.08 | -2.2% | $3.422 | $3.86 | $3.422 | 43,900 | |
| $3.59 | -0.01 | -0.3% | $3.56 | $3.59 | $3.47 | 2,900 | |
| $3.60 | +0.02 | +0.6% | $3.454 | $3.68 | $3.454 | 5,700 | |
| $3.58 | +0.08 | +2.3% | $3.50 | $3.60 | $3.43 | 10,900 | |
| $3.50 | -0.10 | -2.8% | $3.61 | $3.76 | $3.37 | 16,800 | |
| $3.60 | -0.06 | -1.6% | $3.60 | $3.92 | $3.60 | 15,900 | |
| $3.66 | +0.02 | +0.5% | $3.64 | $3.93 | $3.62 | 7,800 | |
| $3.64 | -0.91 | -20.0% | $4.46 | $4.46 | $3.63 | 14,200 | |
| $4.55 | +0.86 | +23.3% | $3.61 | $4.55 | $3.60 | 75,200 | |
| $3.69 | -0.09 | -2.4% | $3.83 | $3.83 | $3.61 | 12,100 | |
| $3.78 | -0.075 | -1.9% | $3.77 | $3.83 | $3.62 | 15,800 | |
| $3.855 | -0.225 | -5.5% | $4.00 | $4.05 | $3.763 | 14,100 | |
| $4.08 | -0.01 | -0.2% | $4.13 | $4.29 | $4.08 | 6,600 | |
| $4.09 | -0.03 | -0.7% | $4.05 | $4.19 | $4.05 | 17,900 | |
| $4.12 | -0.081 | -1.9% | $4.29 | $4.44 | $4.11 | 17,000 | |
| $4.201 | -0.299 | -6.6% | $4.50 | $4.734 | $4.20 | 26,500 | |
| $4.50 | -0.13 | -2.8% | $4.59 | $4.67 | $4.37 | 28,900 | |
| $4.63 | -0.045 | -1.0% | $4.61 | $4.88 | $4.61 | 24,800 | |
| $4.675 | -0.125 | -2.6% | $4.79 | $5.072 | $4.52 | 18,600 | |
| $4.80 | 0.00 | 0.0% | $4.78 | $4.85 | $4.61 | 8,700 | |
| $4.80 | -0.20 | -4.0% | $4.96 | $5.03 | $4.785 | 6,600 | |
| $5.00 | +0.05 | +1.0% | $4.86 | $5.05 | $4.82 | 3,400 | |
| $4.95 | +0.12 | +2.5% | $4.887 | $4.95 | $4.73 | 24,100 | |
| $4.83 | +0.08 | +1.7% | $4.76 | $4.83 | $4.665 | 117,600 | |
| $4.75 | -0.29 | -5.8% | $4.93 | $4.935 | $4.66 | 21,200 | |
| $5.04 | +0.18 | +3.7% | $4.98 | $5.04 | $4.75 | 3,300 | |
| $4.86 | +0.09 | +1.9% | $4.74 | $4.915 | $4.74 | 18,000 | |
| $4.77 | -0.09 | -1.9% | $4.83 | $4.845 | $4.70 | 9,800 | |
| $4.86 | -0.14 | -2.8% | $4.91 | $5.03 | $4.81 | 30,100 | |
| $5.00 | +0.015 | +0.3% | $4.97 | $5.13 | $4.90 | 7,900 | |
| $4.985 | +0.045 | +0.9% | $4.99 | $5.215 | $4.90 | 28,500 | |
| $4.94 | +0.09 | +1.9% | $4.84 | $5.36 | $4.74 | 197,200 | |
| $4.85 | +0.20 | +4.3% | $4.63 | $4.91 | $4.63 | 14,600 | |
| $4.65 | -0.10 | -2.1% | $4.63 | $4.875 | $4.63 | 3,800 | |
| $4.75 | +0.14 | +3.0% | $4.60 | $4.75 | $4.56 | 7,700 | |
| $4.61 | +0.17 | +3.8% | $4.41 | $4.65 | $4.41 | 3,400 | |
| $4.44 | +0.01 | +0.2% | $4.425 | $4.445 | $4.40 | 1,300 | |
| $4.43 | -0.09 | -2.0% | $4.52 | $4.65 | $4.40 | 16,400 | |
| $4.52 | +0.19 | +4.4% | $4.32 | $4.60 | $4.31 | 21,900 | |
| $4.33 | -0.17 | -3.8% | $4.46 | $4.53 | $4.31 | 14,000 | |
| $4.50 | -0.33 | -6.8% | $4.79 | $4.79 | $4.50 | 6,300 | |
| $4.83 | +0.32 | +7.1% | $4.53 | $4.875 | $4.51 | 20,720 | |
| $4.51 | +0.07 | +1.6% | $4.37 | $4.66 | $4.30 | 39,264 | |
| $4.44 | -0.04 | -0.9% | $4.53 | $4.725 | $4.35 | 36,500 | |
| $4.48 | -0.03 | -0.7% | $4.40 | $4.745 | $4.40 | 11,300 |
Splits
1 split · NASDAQ:PASG · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:PASG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jun 25, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement
Latest deck · Jul 22, 2026
Merger or Acquisition (July 2026)
Merger or acquisition · 38 slides
Latest news
Passage Bio and Remix Therapeutics Announce Merger Agreement
Jun 25, 2026
Closed $4.33 (-26.4%) on Jun 25, 2026
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Apr 20, 2026
Closed $6.25 (-46.4%) on Apr 20, 2026
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Mar 3, 2026
Closed $8.00 (-8.9%) on Mar 3, 2026
Passage Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 122 in all · newest Jun 25, 2026 · oldest 2020
- Calls
- 8 calls with a replay · 8 with a transcript · latest Mar 6, 2023
- Decks
- 39 decks · latest Jul 22, 2026
Where Passage Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PASG · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PASG | BOATS | United States | USD |
Valuation
Price/book 252× against a median of 1.8×: the highest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$7.55M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 252×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.94
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Bolt Biotherapeutics, Inc. · NASDAQ:BOLT | US$12.80M | US$18.89M | n/a | 7.5× | n/a | 1.5× | n/a | 2.4× | 0.52 |
| Avai Bio, Inc. · OTC:AVAI | US$12.79M | US$12.67M | n/a | n/a | n/a | n/a | n/a | n/a | 0.28 |
| Neuphoria Therapeutics Inc. · NASDAQ:NEUP | US$12.72M | −US$6.03M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.61 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Median of the others | US$12.60M | US$12.63M | 11.0× | 1.8× | −204.1% | 0.0× | 0.56 |
Forecasts
1 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -14.08 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Athena Countouriotis | Chief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics |
| Derrell D. Porter | Chief Executive Officer and member of the board of directors of cTRL Therapeutics, Inc. |
| William Chou | President and Chief Executive Officer |
| Sandip Kapadia | Chief Financial Officer of Harmony Biosciences Holdings, Inc. |
| Thomas Kassberg | Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. |
Board
| Director | Role |
|---|---|
| Maxine Gowen | Chairwoman |
Events
Calls
| Call | When | Status |
|---|---|---|
| Passage Bio (NASDAQ:PASG) Q4 2022 Earnings Call | Mon, Mar 06, 2023 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q2 2022 Earnings Call | Thu, Aug 04, 2022 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q1 2022 Earnings Call | Mon, May 16, 2022 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q4 2021 Earnings Call | Thu, Mar 03, 2022 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q4 2020 Earnings Call | Wed, Mar 03, 2021 · 8:30 AM ET | Replay |
| Passage Bio (NASDAQ:PASG) Q3 2020 Earnings Call | Tue, Nov 10, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +10.2% |
| Q2 2026 | Aug 10, 2026 · Before open | −1.8% |
| Q1 2026 | May 19, 2026 | +1.6% |
| Q4 2025 | Mar 3, 2026 · After close | +5.5% |
| Q3 2025 | Nov 10, 2025 · After close | +14.8% |
| Q2 2025 | Aug 12, 2025 · Before open | −4.9% |
| Q1 2025 | May 13, 2025 · Before open | −4.2% |
| Q4 2024 | Mar 3, 2025 · Before open | −7.3% |
| Q3 2024 | Nov 13, 2024 · Before open | −12.9% |
| Q2 2024 | Aug 8, 2024 · Before open | −5.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −10.5% |
| Q4 2023 | Mar 4, 2024 · Before open | +1.2% |
| Q3 2023 | Nov 13, 2023 · Before open | 0.0% |
| Q2 2023 | Aug 7, 2023 · Before open | −5.1% |
| Q1 2023 | May 11, 2023 · Before open | −1.0% |
| Q4 2022 | Mar 6, 2023 · Before open | 0.0% |
| Q3 2022 | Nov 10, 2022 · Before open | +10.8% |
| Q2 2022 | Aug 4, 2022 · Before open | +0.9% |
| Q1 2022 | May 16, 2022 · Before open | −7.7% |
| Q4 2021 | Mar 3, 2022 · Before open | −11.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (July 2026) | Merger or acquisition | 38 slides | Jul 22, 2026 |
| Merger or Acquisition (June 2026) | Merger or acquisition | 36 slides | Jun 24, 2026 |
| Investor Presentation (April 2026) | Investor deck | 33 slides | Apr 20, 2026 |
| Investor Presentation (March 2026) | Investor deck | 34 slides | Mar 3, 2026 |
| Investor Presentation (January 2026) | Investor deck | 35 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | Nov 10, 2025 |
| Investor Presentation (August 2025) | Investor deck | 31 slides | Aug 12, 2025 |
| Investor Presentation (June 2025) | Investor deck | 32 slides | Jun 23, 2025 |
| Investor Presentation (May 2025) | Investor deck | 31 slides | May 13, 2025 |
| AD/PD 2025 International Conference | Conference | 14 slides | Apr 3, 2025 |
All 39 decks
IPO
Priced at US$18.00 a share on Feb 27, 2020.
- Price
- US$18.00 a share
- Shares offered
- 12,000,000 shares of common stock
- Offering size
- US$216 million
- Underwriters' option
- Up to 1,800,000 more shares
- Listing
- PASG on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Chardan · In the order on the cover
- Shares delivered
- On or about Mar 3, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 6, 2019 |
| Filed publicly | Feb 3, 2020 |
| Amended twice | Newest Feb 27, 2020 |
| Shares registered with an exchange | Feb 18, 2020 |
| Declared effective by the SEC | Feb 27, 2020 |
| Final prospectus, with the price | Feb 28, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 28, 2020 |
| EFFECT · Notice that a registration is effective | Feb 27, 2020 |
| S-1MEF · Registration of more shares for the same offering | Feb 27, 2020 |
| S-1/A · Registration statement, amended | Feb 27, 2020 |
| CORRESP · Letter to the SEC | Feb 25, 2020 |
| CORRESP · Letter to the SEC | Feb 25, 2020 |
| CERT · Exchange's certificate of listing | Feb 25, 2020 |
| FWP · Free writing prospectus | Feb 20, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 18, 2020 |
| S-1/A · Registration statement, amended | Feb 18, 2020 |
All 16 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Feb 7, 2020 |
| S-1 · Registration statement | Feb 3, 2020 |
| DRSLTR · Letter to the SEC with a draft | Jan 10, 2020 |
| DRS/A · Draft registration statement, amended | Jan 10, 2020 |
| UPLOAD · Letter from the SEC | Jan 3, 2020 |
| DRS · Draft registration statement | Dec 6, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 28, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 728.0K | 3.08M | 3.72M | 3.68M | 1.54M | 800.0K | 134.0K | |
| Gross profit | -728.0K | -3.08M | -3.72M | -3.68M | -1.54M | -800.0K | -134.0K | |
| Research and development | 23.3M | 40.2M | 61.4M | 86.1M | 117.7M | 81.8M | 3.03M | 9.17M |
| Selling, general and administrative | 19.9M | 25.0M | 41.6M | 49.3M | 60.1M | 30.1M | 6.95M | 928.0K |
| Operating income | -49.3M | -70.4M | -108.4M | -138.4M | -185.7M | -112.9M | -37.2M | -13.5M |
| Depreciation and amortization | 728.0K | 3.08M | 3.72M | 3.68M | 1.54M | 800.0K | 134.0K | 134.0K |
| EBITDA | -48.6M | -67.3M | -104.7M | -134.7M | -184.2M | -112.1M | -37.1M | -13.3M |
| Interest expense | 2.27M | 343.0K | 670.0K | 8.45M | 696.0K | |||
| Income before tax | -45.5M | -64.8M | -102.1M | -136.1M | -185.4M | -112.2M | -45.6M | -12.8M |
| Income tax | 0 | 0 | 5.39M | 731.0K | 6.11M | -470.0K | 8.95M | -696.0K |
| Net income | -45.5M | -64.8M | -102.1M | -136.1M | -185.4M | -112.2M | -45.6M | -12.8M |
| Earnings per share, basic | -14.35 | -21.04 | -1.86 | -2.50 | -3.48 | -2.91 | -10.77 | -10.66 |
| Earnings per share, diluted | -14.35 | -21.04 | -1.86 | -2.50 | -3.48 | -2.91 | -10.77 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 46.3M | 37.6M | 21.7M | 34.6M | 129.0M | 135.0M | 158.9M | 24.9M |
| Short-term investments | 0 | 39.2M | 92.6M | 155.0M | 186.8M | 169.8M | ||
| Receivables | 4.27M | 6.20M | 8.03M | |||||
| Current assets | 47.8M | 78.8M | 118.0M | 197.0M | 325.1M | 317.2M | 165.8M | 33.4M |
| Property, plant and equipment | 4.11M | 9.33M | 15.3M | 22.5M | 23.8M | 2.79M | 1.09M | 28.0K |
| Total assets | 62.3M | 102.4M | 150.5M | 243.5M | 355.1M | 328.0M | 178.6M | 33.5M |
| Accounts payable | 1.11M | 742.0K | 1.30M | 4.07M | 9.45M | 5.26M | 629.0K | 212.0K |
| Current liabilities | 23.1M | 19.4M | 16.3M | 18.4M | 29.5M | 21.2M | 3.68M | 307.0K |
| Total debt | 24.0M | 25.5M | 26.3M | 27.1M | ||||
| Total liabilities | 43.5M | 41.2M | 39.3M | 42.2M | 36.4M | 23.3M | 4.26M | 45.6M |
| Shareholders' equity | 18.8M | 61.3M | 111.3M | 201.4M | 318.7M | 304.7M | -56.3M | -12.2M |
| Shares outstanding | 3.18M | 3.16M | 54.9M | 54.6M | 54.2M | 45.6M | 4.29M | 1.20M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31.5M | -48.0M | -78.3M | -118.2M | -126.9M | -80.5M | -39.9M | -18.6M |
| Capital spending | 0 | -34.0K | -146.0K | -5.27M | -25.6M | -1.65M | -1.69M | -2.54M |
| Free cash flow | -31.5M | -48.0M | -78.4M | -123.5M | -152.5M | -82.2M | -41.6M | -21.1M |
| Cash from investing | 40.2M | 54.9M | 65.2M | 25.2M | -45.8M | -172.1M | -1.69M | -2.54M |
| Cash from financing | 23.0K | 8.87M | 135.0K | -1.35M | 166.7M | 228.8M | 175.6M | 46.0M |
| Share buybacks | 23.0K | 97.0K | 135.0K | 304.0K | 887.0K | 284.0K | ||
| Change in cash | 8.73M | 15.9M | -12.9M | -94.4M | -6.04M | -23.9M | 134.0M | 24.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Oct 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 9, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 8, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 5, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Sep 21, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-4/A · Registration statement, amended | Sep 2, 2026 | Offer document | SEC |
| 425 | Sep 2, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 425 | Jul 21, 2026 | Other filings | SEC |
| S-4 · Registration statement | Jul 21, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2026 | Big-stake notice | SEC |
| 425 | Jun 24, 2026 | Other filings | SEC |
| 425 | Jun 24, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 24, 2026 | Material contract | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 26, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 7, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 7, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K · Current report | Sep 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 24, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 21, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 21, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 9, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 8-K · Current report | May 30, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 15, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Mar 5, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 8-K · Current report | Sep 10, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 6, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 9, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 8-K · Current report | Jul 16, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | May 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | May 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 12, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 12, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 9, 2024 | Annual report | SEC |
| SC 13G · Big-stake notice | Mar 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 7, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2024 | Offer document | SEC |
| S-3 · Registration statement | Mar 4, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2024 | Results | SEC |
| 8-K · Current report | Feb 29, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 29, 2023 | Current report | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 9, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Sep 1, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 31, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 31, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jul 28, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 28, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 20, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 29, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 29, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 15, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 8-K · Current report | May 26, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 4 · Change in ownership | Apr 20, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 14, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2023 | Meeting notice | SEC |
This page holds 200 of 447 filings. Open Filings
Cap table
Built by 6ix from Passage Bio, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 3,217,810
- Fully diluted
- 3,217,810
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 3,217,810 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 3,217,810 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Maxine Gowen Other companies: Aclaris Therapeutics, Inc. (Director · Since at least Jul 2, 2019); Trevena, Inc. (Director · Since at least Jan 30, 2014); Aceragen Inc. (Director · Jan 4, 2015 – Aug 10, 2023 · Past); Akebia Therapeutics, Inc. (Director · Jul 28, 2014 – Jun 5, 2020 · Past); Human Genome Sciences Inc (Director · Feb 15, 2008 – Jul 30, 2012 · Past) | Chairwoman · Since at least Feb 18, 2021 |
| Jill Quigley Other companies: Chemomab Therapeutics Ltd. (Board Director · Since at least Jun 16, 2022); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 4, 2021) | Chief Operating Officer · Feb 27, 2020 – Dec 8, 2021 · Past |
| Saqib Islam Other companies: SpringWorks Therapeutics Inc (Chief Executive Officer, Director · Since at least Jan 7, 2021); ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020) | Director · Since at least May 27, 2021 |
| Derrell D. Porter Other companies: Acumen Pharmaceuticals, Inc. (CEO: cTRL Therapeutics, Inc. · Since at least Jan 4, 2023) | Director · Since at least May 27, 2021 |
| Mark S Forman Other companies: Ventyx Biosciences Inc (Chief Medical Officer · Since at least Aug 12, 2024) | CHIEF MEDICAL OFFICER · Mar 30, 2022 – Mar 15, 2024 · Past |
| Monika Maria Toernsen Other companies: Immunic, Inc. (Director · Since at least Jul 5, 2022) | Chief Commercial Officer · Jul 19, 2021 – Sep 15, 2022 · Past |
| Thomas Kassberg Other companies: Ultragenyx Pharmaceutical Inc. (CBO & EVP · Oct 23, 2023 – Mar 1, 2025 · Past) | Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. · Since at least Sep 10, 2024 |
| Athena Countouriotis | Chief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics · Since at least Nov 5, 2026 |
| Bruce A Goldsmith | CEO and President, Director · Feb 27, 2020 – May 27, 2022 · Past |
| Dolan Sondhi | Director · Since at least Jul 27, 2023 |
All 14 people
| Person | Seat |
|---|---|
| Edgar B Cale | GC & CORPORATE SECRETARY · Feb 27, 2020 – Mar 15, 2025 · Past |
| Eliseo Oreste Salinas | Chief Res. & Develop Officer · Mar 22, 2021 – Feb 10, 2022 · Past |
| Sandip Kapadia | Chief Financial Officer of Harmony Biosciences Holdings, Inc. · Since at least Nov 5, 2026 |
| William Chou | President and Chief Executive Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Passage Bio, Inc.